Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura

Journal of Clinical Pathology

Volumn 53, Issue 7, 2000, Pages 497-501

  Allford, S L ^a   Machin, S J ^a  

^a UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIUM; CYCLOSPORIN; FIBRIN; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; LACTATE DEHYDROGENASE; MITOMYCIN C; ORAL CONTRACEPTIVE AGENT; PADGEM PROTEIN; PROTEINASE; QUININE; TICLOPIDINE; VON WILLEBRAND FACTOR;

ARTICLE; BARTONELLA BACILLIFORMIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

FEMALE; HEMOLYSIS; HUMANS; MALE; PLATELET AGGREGATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 0033920541     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.53.7.497     Document Type: Article

References (36)

1. 1 Moschowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescrihed disease. Proceedings of the New York Pathological Society 1924;24:21-4.
2. 2 Shumak KH, Rock GA, Nair RC, Members of the Canadian Apheresis Group. Late relapses successfully treated for thrombotic thrombocytopenic purpura. Ann Intern Med 1995;122:569-72.
3. 3 Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. Ann Intern Med 1998;128:541-4.
4. 4 Tarantolo ST, Landmark JD, Iwen PC, et al. Bartonella-like erythrocyte inclusions in thrombotic thrombocytopenic purpura. Lancat 1997;350;1602.
5. 5 Chintagumpala MM, Hurwitz RL, Moake JL, et al. Chronic relapsing thrombotic thrombocytopenic purpura in infants with large von Willebrand factor multimers during remission. J Pediatr 1992;120:49-53.
6. 6 Harkness DR, Byrnes JJ, Lian EC-Y, et al. Hazard of platelet transfusion in thrombotic thrombocytopenic purpura. JAMA 1981;246:1931-3.
7. 7 Asada Y, Sumiyoshi A, Hayashi T, et al. Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 1985;38:469-79.
8. 8 Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986;78:1456-61.
9. 9 Moake JL, Turner NA, Stathopoulos NA, et al. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988;71: 1366-74.
10. 10 Peterson DM, Stathopoulos NA, Giorgio TD, et al. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb IIIa. Bood 1987;69:625-8.
11. 11 Moake J, Chintagumpala M, Turner N, et al. Solvent/ detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura. Blood 1994;84:490-7.
12. 12 Karpman D, Lethagen S, Kristoffersson A-C, et al. Von Willebrand factor mediates increased platelet retention in recurrent thrombotic thrombocytopenic purpura. Thromb Haemost 1997;78:1456-62.
13. 13 Tsai H-M, Angel RL, Hatter VB, et al. The high molecular weight form of endotheliai cell von Willebrand factor is released by the regulated pathway. Br J Haematol 1991;79: 239-45.
14. 14 O'Brien JR, Etherington MD. The endothelial von Willebrand factor in venous occlusion blood. Thromb Haemost 1997;78:1528-9.
15. 15 Zimmerman TS, Dent JA, Ruggeri ZM, et al. Subunit composition of plasma von Willebrand factor. J Clin Invest 1986;77:947-51.
16. 16 Tsai H-M, Angel RL, Susan II. Subunit composition of plasma von Willebrand factor multimers: evidence for a non-proteolytic mechanism resulting in apparent increase in proteolytic fragments. Thromb Res 1991;63:179-88.
17. 17 Dent JA, Galbusera M, Ruggeri ZM. Heterogeneity of plasma von Willebrand factor multimers resulting form proteolysis of the constituent subunit. J Clin Invest 1991;88:774-82.
18. 18 Phillips MD, Moake JL, Nolasco L, et al. Plasma von Willebrand factor processing activity functions like a disulfide bond reductase: reversible decrease of multimer size [abstract]. Thromb Haemost 1993;69:2342.
19. 19 Furlan M, Robles R, Lämmle B. Partial purification of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996;87:4223-34.
20. 20 Tsai H-M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 1996;87:4235-44.
21. 21 Tsai H-M, Susan II, Angel RL. Shear stress enhances proteolysis of von Willebrand factor in normal plasma. Blood 1994;83:2171-9.
22. 22 Furlan M, Robles R, Solenthaler M, et al. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997;89:3097-103.
23. 23 Furlan M, Robles R, Galbusera M, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998,339:1578-84.
24. 24 Tsai H-M, Lian EC-Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-94.
25. 25 Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Hematol 1998;58:189-94.
26. 26 Chong BH, Murray B, Berndt MC, et al. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 1994;83:1535-41.
27. 27 Katayama M, Handa M, Araki Y, et al. Soluble P-selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome. Br J Haematol 1993;84:702-10.
28. 28 Wada H, Kaneko T, Ohiwa M, et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993;44:101-5.
29. 29 Anthony MT, Zeigler ZR, Lister J, et al. Plasminogen activator inhibitor (PAI-1) antigen levels in primary TTP and secondary TTP post-bone marrow transplantation. Am J Hematol 1998;59:9-14.
30. 30 Kobayashi M, Wada H, Wakita Y, et al. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1995;73:10-4.
31. 31 Laurence J, Mitra D, Steiner M, et al. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cell lines. Blood 1996;87:3245-54.
32. 32 Mitra D, Jaffe EA, Weksler B, et al. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells. Blood 1997;89:1224-34.
33. 33 Chow TW, Turner NA, Chintagumpala M, et al. Increased von Willebrand factor binding to platelets in single episode and recurrent types of thrombotic thrombocytopenic purpura. Am J Hematol 1998;57:293-302.
34. 34 Moake JL, McPherson PD. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. Am J Med 1989;87:3-9N.
35. 35 Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999;81:8-13.
36. 36 Van der Plas RM, Schiphorst ME, Huizinga EG, et al. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999;93:3798-802.